MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Bladder and Urothelial Cancer Treatments
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,070 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,070 works in the cohort · of 4,299,418page 33 of 62

Labels cover 8 of 3,070 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,070 of 3,070 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affvenueunlabeled
Bladder cancer, ESMO 2016
Alan So
2016· review· en· Canadian Urological Association Journal· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affunlabeled
Molecular pathology of bladder cancer
Antonio López-Beltrán, Ana Blanca, Michelle R. Downes, Alessia Cimadamore, Rodolfo Montironi, Liang Cheng
2025· review· en· Histopathology· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affunlabeled
A phase III, randomized, open label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SOC) chemotherapy and durvalumab in combination with tremelimumab and SOC chemotherapy versus SOC chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
Matt D. Galsky, Andrea Necchi, Srikala S. Sridhar, Osamu Ogawa, Natasha Angra, Stephan Hois +3 more
2019· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affno abstractunlabeled
Plasmacytoid Urothelial Carcinoma of the Urinary Bladder
Hossein M. Yazdi, Eric Saltel, Şeyda Erdoğan, William A. Stinson, Ilias Caggianos, Christopher Morash
2006· article· en· European Urology· Medicine
machine prediction:candidate · noneconsensus · none
5
citations
affno abstractunlabeled
Erratum to “European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel” [Eur. Urol. 79(4) (2021) 480–488]
Richard Sylvester, Oscar Rodríguez, Virginia Hernández, Diana Turturica, Lenka Bauerová, Harman Max Bruins +54 more
2023· erratum· en· European Urology· Medicine
machine prediction:candidate · noneconsensus · none
5
citations

How this was built: Screen · Findings · About